|
|
MircoRNA 在直肠癌中的研究进展 |
杜哲明1, 邓莉2综述, 周育宏1审校 |
1.330030 南昌,武警江西总队医院外一科; 2.330006,南昌市第三医院医务科 |
|
[1] |
Rui Y, Yao L, FeiLW, et al.MicroRNAs as diagnostic and prognostic biomarkers in colorectal cancer[J].World J Gastrointest Oncol, 2016, 8(4): 330-340.
|
[2] |
Petra V F, Martin P, Lenka R, et al.Genome-wide microRNA expression profiling in primary tumors and matched liver metastasis of patients with colorectal cancer[J].Cancer Genomics Proteomics, 2016, 13: 311-316.
|
[3] |
Dong Y, Wu W K, Wu C W,et al.MicroRNA dysregulation in colorectal cancer: a clinical perspective[J].Br J Cancer, 2011, 104: 893-898.
|
[4] |
Chi D, Zhou D.MicroRNAs in colorectal carcinoma-from pathogenesis to therapy[J].J Exp Clin Cancer Res, 2016, 35:43.
|
[5] |
Asanganiv I A, Rasheed S A, Nikolova D A, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer[J].Oncogene, 2008, 27: 2128-2136.
|
[6] |
Valeri N, Gasparini P,Braconi C, et al. MicroRNA-21 induces resistance to 5-flfluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2)[J].Proc Natl Acad Sci U S A, 2010, 107: 21098-21103.
|
[7] |
Deng J, Lei W, Fu J C, et al. Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro[J].Biochem Biophys Res Commun, 2014, 443: 789-795.
|
[8] |
Kim S A, Kim I,Yoon S K, et al. Indirect modulation of sensitivity to 5-flfluorouracil by microRNA-96 in human colorectal cancer cells[J].Arch Pharm Res, 2015, 38: 239-248.
|
[9] |
Catela I T,Voss G,Cornella H, et al.MicroRNAs as cancer therapeutics: a step closer to clinical application[J].Cancer Lett, 2017, 407: 113-122.
|
[10] |
Valeri N,Gasparini P, Fabbri M, et al.Modulation of mismatch repair and genomic stability by miR-155[J].Proc Natl Acad Sci U S A, 2010, 107: 6982-6987.
|
[11] |
Rodriguez A C, Fuentes M E, Xiao L, et al. Combining anti-mir-155 with chemotherapy for the treatment of lung cancers[J]. Clin Cancer Res, 2017, 23: 2891-2904.
|
[12] |
Ling H, Pickard K, Ivan C, et al.The clinical and biological signifificance of MIR-224 expression in colorectal cancer metastasis[J]. Gut, 2016, 65: 977-989.
|
[13] |
CordesK R, Sheehy N T,White M P, et al. MiR-145 and miR-143 regulate smooth muscle cell fate and plasticity[J]. Nature, 2009, 460, 705-710.
|
[14] |
Yuan F, Sun R, Li L,et al.A functional variant rs353292 in the flflanking region of miR-143/145 contributes to the risk of colorectal cancer[J].Sci Rep, 2016,6: 30195.
|
[15] |
Banerjee N, Kim H, Talcott S, et al. Pomegranate polyphenolics suppressed azoxymethane-induced colorectal aberrantcrypt foci and inflammation : possible role of miR-126/VCAM-1 and miR-126/PI3K/AKT/mTOR[J].Carcinogenesis, 2013, 34: 2814-2822.
|
[16] |
Lee J J, Drakaki A, Iliopoulos D, et al. MiR-27b targets PPARgamma to inhibit growth, tumor progression and the inflflammatory response in neuroblastoma cells[J].Oncogene, 2012, 31: 3818-3825.
|
[17] |
Iwaya T, Yokobori T, Nishida N, et al.Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway[J]. Carcinogenesis, 2012, 33: 2391-2397.
|
[18] |
Sun J Y, Huang Y, Li J P, et al. MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting beta-catenin[J]. Biochem Biophys Res Commun, 2012, 420: 787-792.
|
[19] |
Li Y,Zhu X, Xu W,et al.MiR-330 regulates the proliferation of colorectal cancer cells by targeting Cdc42[J].Biochem Biophys Res Commun, 2013, 431: 560-565.
|
[20] |
Chai J, Wang S, Han D, et al. MicroRNA-455 inhibits proliferation and invasion of colorectal cancer by targeting RAF proto-oncogene serine/threonine-protein kinase[J].Tumour Biol, 2015, 36: 1313-1321.
|
[21] |
Xu K,Liu X, Mao X, et al. MicroRNA-149 suppresses colorectal cancer cell migration and invasion by directly targeting forkhead box transcription factor FOXM1[J]. Cell Physiol Biochem, 2015, 35: 499-515.
|
[22] |
Toiyama Y, Hur K, Tanaka K,et al. Serum miR-200c is a novel prognostic and metastasispredictive biomarker in patients with colorectal cancer[J]. Ann Surg, 2014, 259: 735-743.
|
[23] |
Schetter A J,Leung S Y,Sohn J J, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma[J].JAMA, 2008, 299: 425-436.
|
[24] |
Kjaer F S, Hansen T F, Nielsen B S, et al. The prognostic importance of miR-21 in stage II colon cancer: a population-based study [J].Br J Cancer, 2012, 107: 1169-1174.
|
[25] |
Hong L C, Shao J H, Ai H L, et al. Correlation between expression of miR-155 in colon cancer and serum carcinoembryonic antigen level and its contribution to recurrence and metastasis forecast[J].Saudi Med J, 2014, 35: 547-553.
|
[26] |
Kjersem J B, Ikdahl T, Lingjaerde O C, et al. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment[J]. Mol Oncol, 2014, 8: 59-67.
|
[27] |
Xu K, Liang X, Cui D, et al. MiR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug sensitivity in human colorectal carcinoma cells[J]. Mol Carcinog, 2013, 52: 70-78.
|
[28] |
Gao Y,Liu Z, Ding Z,et al.MircoRNA-155 increases colon cancer chemoresistance to cisplatin by targering forkhead box O3[J]. Oncol Lett,2018,15(4);4781-4788.
|
[29] |
Misso G, Di M M, De R G, et al. Mir-34: a new weapon against cancer? [J].Mol Ther Nucleic Acids, 2014, 3: e194.
|
[30] |
Tang W, Zhu Y, Gao J, et al. MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4[J]. Br J Cancer, 2014, 110: 450-458.
|
[31] |
Zhao J,Tang N,Wu K,et al.Mir-21 simultaneously regulates ERK1 signaling in HSC activation and hepatocyte EMT in hepatic fibrosis[J].PLoS One,2014,9:e108005.
|
[32] |
Ajay G, Oscar A T, Shu S T.Exosomal microRNA biomarkers: emerging frontiers in colorectal and other human cancers[J].Expert Rev Mol Diagn, 2016, 16(5): 553-567.
|
[33] |
Petra V F, Alena S K, Tomas G, et al.MicroRNA biogenesis pathway genes are deregulated in colorectal cancer[J].Int J Mol Sci, 2019, 20: 4460.
|
[1] |
李静, 张燕双, 徐梦楠, 张静, 李白容, 宁守斌, 顾国利. 自膨式金属支架治疗结直肠癌患者肠梗阻的价值[J]. 武警医学, 2020, 31(8): 683-687. |
[2] |
周迪, 路明亮, 董岩. ω-3多不饱和脂肪酸治疗结直肠癌研究进展[J]. 武警医学, 2020, 31(3): 243-246. |
[3] |
林杨杨, 李钦峰. 瘰疬性苔藓的研究进展[J]. 武警医学, 2019, 30(7): 633-636. |
[4] |
杨亚会, 邓牡红, 闫思思, 黄芳芳, 谢森, 陈志杰, 王瑞藏. 直肠癌脑膜转移致颅高压危象合并癫痫1例护理体会[J]. 武警医学, 2019, 30(6): 549-549. |
[5] |
王东轶, 陆乐, 蔡辉. 神经精神狼疮的诊疗进展[J]. 武警医学, 2019, 30(5): 444-448. |
[6] |
陈浩, 熊永强, 黄河. 腹腔镜直肠癌根治术后吻合口瘘的危险因素[J]. 武警医学, 2019, 30(4): 322-324. |
[7] |
贾珍,罗梦琳. 参麦注射液对结直肠癌化疗患者免疫功能的影响[J]. 武警医学, 2019, 30(3): 221-223. |
[8] |
王耀彬, 温友信, 陈艳琼, 陈海英. MRI增强与直肠双重超声造影在直肠癌术前TN分期中的应用效果比较[J]. 武警医学, 2019, 30(12): 1029-1031. |
[9] |
周腾, 郑皓, 达布·西力特, 蔡晓军, 贾元利, 韩承新. 术前经肛间断低负压冲洗引流治疗结直肠癌合并肠梗阻的效果[J]. 武警医学, 2018, 29(9): 892-894. |
[10] |
何双智, 金克敏. 结直肠癌同时肝转移运用快速康复理念同期切除的效果[J]. 武警医学, 2017, 28(8): 772-775. |
[11] |
张 忠,金伟森. 结直肠癌患者术前血清癌胚抗原及糖类抗原19-9阳性与临床病理学特征的关系[J]. 武警医学, 2017, 28(1): 26-29. |
[12] |
郑昊宇,张旭毅,张 毅. 扩散加权成像表观扩散系数及其相对值测定对直肠癌周围淋巴结定性诊断的价值[J]. 武警医学, 2017, 28(1): 64-67. |
[13] |
薛彦俊,傅文杰,李萍. 单孔腹腔镜手术对结直肠癌的治疗价值[J]. 武警医学, 2016, 27(11): 1138-1141. |
[14] |
杨阳, 丁毅, 李泽楠, 张冬, 杨旭华, 金伟森. 腹腔镜下超低位直肠癌根治术8例[J]. 武警医学, 2015, 26(6): 624-625. |
[15] |
李辉, 高强, 王翼腾, 张丽明, 陈虹综述李覃审校. 应用小鼠建立特应性皮炎模型的研究进展[J]. 武警医学, 2015, 26(1): 99-102. |
|
|
|
|